First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
The restructured biotech’s new lead project enters phase 1.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
The private biotech adds another asset to J&J’s prostate cancer pipeline.
The company will imminently start its third pivotal trial of PF-08634404.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
The company ditches lorigerlimab in prostate cancer.